ICER takes on Aetion’s RWE platform

By Jenni Spinner contact

- Last updated on GMT

ICER takes on Aetion’s RWE platform

Related tags: Real-world evidence, Real-world data

The ICER plans to harness the company’s technology to expand use of real-world evidence.

As a health technology assessment (HTA) organization, ICER works to evaluate how emerging medical interventions serve to improve patients’ lives. It also suggests benchmark prices that fall in line with an intervention’s benefit to patients and the overall healthcare system.

In its 2020 Value Assessment Framework, ICER outlined plans to generate RWE for assessments. Additionally, the group recently laid the groundwork for harnessing RWE in two-year reevaluations of US FDA-approved drugs, under accelerated approval routes.

Broad health industry benefits

An Aetion spokesperson told Outsourcing-Pharma that the use of RWE benefits people across the healthcare spectrum.

It furthers ICER’s mission of catalyzing a movement toward fair pricing, fair access, and future innovation across the entire US health system​,” they said.

Pamela Bradt, chief scientific officer for ICER, said analytics from Aetion’s Evidence Platform will empower the organization to more efficiently gather evidence for its review process.

“Through this partnership, we aim to set new standards for how RWE can better inform the consequential decisions that biopharma manufacturers, insurers, and other stakeholders make every single day around drug pricing and patient access,”​ Bradt said.

Sharing information

According to Aetion, protocols developed via the partnership with ICER will be included in assessments that ICER shares publicly. The open sharing of information, in turn, will benefit other stakeholders in the industry.

Integrating RWE into ICER’s assessments will advance how we as a health care industry—and a society—determine value​,” said Carolyn Magill, CEO of Aetion.

Aetion has partnered with several organizations and companies to promote use of RWE. In August 2018, Harvard Medical School and Brigham’s Women’s Hospital​ tapped the Evidence Platform to support their Reproducible Evidence Practices to Enhance and Achieve Transparency (REPEAT) program.

Additionally, in October 2019, McKesson and Aetion​ announced a collaboration to advance the use of RWE in cancer research.

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 15-Aug-2022 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Related suppliers

Follow us


View more